Stem definition | Drug id | CAS RN |
---|---|---|
antineoplastics; thymidylate synthetase inhibitors | 2353 | 112887-68-0 |
Molecule | Description |
---|---|
Synonyms:
|
|
None
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 50 % | Benet LZ, Broccatelli F, Oprea TI |
BA (Bioavailability) | 15 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 6.57 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 0.90 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.05 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 140 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Jan. 1, 1996 | YEAR INTRODUCED |
None
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Myelosuppression | 91.69 | 45.20 | 27 | 598 | 19238 | 34937068 |
Bone marrow failure | 68.80 | 45.20 | 24 | 601 | 29229 | 34927077 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Myelosuppression | 146.85 | 44.88 | 42 | 916 | 40254 | 79703176 |
Bone marrow failure | 87.74 | 44.88 | 30 | 928 | 51077 | 79692353 |
Disease progression | 58.86 | 44.88 | 33 | 925 | 184329 | 79559101 |
Neurotoxicity | 55.38 | 44.88 | 19 | 939 | 32499 | 79710931 |
Diarrhoea | 49.01 | 44.88 | 56 | 902 | 880433 | 78862997 |
None
Source | Code | Description |
---|---|---|
ATC | L01BA03 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS ANTIMETABOLITES Folic acid analogues |
MeSH PA | D000963 | Antimetabolites |
MeSH PA | D000964 | Antimetabolites, Antineoplastic |
MeSH PA | D000970 | Antineoplastic Agents |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D005493 | Folic Acid Antagonists |
MeSH PA | D009676 | Noxae |
None
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 4.16 | acidic |
pKa2 | 5.61 | acidic |
pKa3 | 9.02 | acidic |
pKa4 | 12.86 | acidic |
pKa5 | 3.53 | Basic |
pKa6 | 2.67 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Thymidylate synthase | Enzyme | IC50 | 6.59 | CHEMBL | |||||
Dihydrofolate reductase | Enzyme | IC50 | 4.68 | WOMBAT-PK | |||||
Folate receptor beta | Membrane receptor | IC50 | 7.66 | CHEMBL | |||||
Proton-coupled folate transporter | Transporter | IC50 | 7 | CHEMBL | |||||
Folate transporter 1 | Transporter | IC50 | 8.20 | CHEMBL | |||||
Folate receptor alpha | Membrane receptor | IC50 | 7.82 | CHEMBL | |||||
Bifunctional dihydrofolate reductase-thymidylate synthase | Enzyme | IC50 | 6.32 | CHEMBL | |||||
Dihydrofolate reductase | Enzyme | IC50 | 4.64 | CHEMBL | |||||
Thymidylate synthase | Enzyme | IC50 | 5.24 | WOMBAT-PK | |||||
Thymidylate synthase | Enzyme | Ki | 6.38 | CHEMBL | |||||
Thymidylate synthase | Enzyme | IC50 | 6.05 | CHEMBL | |||||
Thymidylate synthase | Enzyme | IC50 | 5.10 | CHEMBL | |||||
Dihydrofolate reductase | Enzyme | IC50 | 4.64 | CHEMBL | |||||
Thymidylate synthase | Enzyme | IC50 | 5.28 | CHEMBL |
ID | Source |
---|---|
D01064 | KEGG_DRUG |
C0677667 | UMLSCUI |
CHEBI:5847 | CHEBI |
D16 | PDB_CHEM_ID |
CHEMBL225071 | ChEMBL_ID |
DB00293 | DRUGBANK_ID |
C068874 | MESH_SUPPLEMENTAL_RECORD_UI |
7403 | IUPHAR_LIGAND_ID |
7319 | INN_ID |
FCB9EGG971 | UNII |
135400182 | PUBCHEM_CID |
196239 | RXNORM |
005929 | NDDF |
326914003 | SNOMEDCT_US |
395857008 | SNOMEDCT_US |
None